International Stem Cell Corp (ISCO): Capital Expenditures
$43.0K
Year ended 2025-12-31
$36.0K
Trailing 12 months to 2026-06-30
+250.3%
3-year compound annual growth
+9.0%
5-year compound annual growth
+2.1%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $43.0K | -74.1% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $166.0K | +107.5% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $80.0K | n/m | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $1.0K | -95.7% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $23.0K | -17.9% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $28.0K | -82.9% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $164.0K | -11.4% | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | $185.0K | +65.2% | 2020-06-01, From 2018-01-01 |
| 2017-12-31 | $112.0K | -51.5% | 2019-04-15, From 2017-01-01 |
| 2016-12-31 | $231.0K | +560.0% | 2018-04-09, From 2016-01-01 |
| 2015-12-31 | $35.0K | -87.9% | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | $290.0K | +73.7% | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | $167.0K | n/a | 2015-03-30, From 2013-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| International Stem Cell Corp (ISCO) | 2025-12-31 | $43.0K | -74.1% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $719.0K | +96.4% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $2.00M | -76.8% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $1.04M | +190.5% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $18.0K | -86.3% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $8.21M | +78.5% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $111.0K | -8.3% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $72.0K | +75.6% |
| Adagene Inc. (ADAG) | 2025-12-31 | $17.1K | -49.2% |
Compare ISCO, BIOA, PGEN, JANX side by side · Screen every company in Pharmaceutical Preparations ↗